Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Boai NKY Medical Holdings Ltd. (300109.SZ)
Jiaozuo, CN
Boai NKY Medical Holdings Ltd. is an international enterprise specializing in the development, production, and global distribution of polyvinylpyrrolidone (PVP) series products. Its extensive product portfolio features pharmaceutical excipients such as Povidone, Crospovidone, and Copovidone, marketed under the KoVidone and PolyKoVidone brand lines. The company also manufactures OraRez PVM/MA copolymers and their derivatives, which are specialized functional polymers vital for bioadhesive and mucoadhesive applications. Additionally, it supplies KoVidone-1, a broad-spectrum agent with biocidal, antifungal, and antiviral efficacy. Further offerings encompass a wide array of chemical solutions, including pharmaceutical solvents, intermediates, various polymers, and vinyl and vinyl ether compounds. Specific branded products like PolyViscol, KoVidone I, WhiVidone, and PVPP are also part of their catalog. These diverse chemical components find integral application across numerous industries, including pharmaceuticals, industrial processes, oral care products, cosmetics, and the food and beverage sector. Founded in Heping, China, in 1987, the company was initially known as Boai NKY Pharmaceuticals Ltd. It transitioned to its current designation, Boai NKY Medical Holdings Ltd., in March 2016.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.76% | -3.19% | -6.87% | -12.12% | -2.71% | +4.94% | +5.32% | +23.56% | +121.91% | -11.59% | +120.80% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - General: +6.6%-26.7% Q1'26: +5.3% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%-45.8% Q1'26: -23.5% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+13.4% ★ Q1'26: -5.8% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+20.7% ★ Q1'26: +22.7% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+5.9% Q1'26: +8.1% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%+0.4% Q1'26: +5.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×0.90× ★ Q1'26: 1.04× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
290.64M
est: 450.00M (-35.4%)
|
400.62M
est: 408.00M (-1.8%)
|
488.58M
est: 523.00M (-6.6%)
|
698.28M
est: 450.00M (+55.2%)
|
924.43M
est: 408.00M (+126.6%)
|
978.53M
est: 523.00M (+87.1%)
|
648.00M
est.
|
1.22B
est: 1.49B (-18.3%)
|
1.49B
est: 1.73B (-14.1%)
|
1.58B
est: 1.73B (-8.4%)
|
1.61B
est: 1.65B (-2.8%)
|
1.18B
est: 1.52B (-22.5%)
|
1.65B
1.65B – 1.65B
+8.7% YoY
|
1.82B
1.82B – 1.82B
+10.2% YoY
|
| EBITDA |
92.62M
est: 125.14M (-26.0%)
|
132.93M
est: 113.46M (+17.2%)
|
147.91M
est: 145.44M (+1.7%)
|
178.61M
est: 125.14M (+42.7%)
|
251.67M
est: 113.46M (+121.8%)
|
172.18M
est: 145.44M (+18.4%)
|
180.20M
est.
|
400.51M
est: 415.46M (-3.6%)
|
454.57M
est: 480.81M (-5.5%)
|
662.57M
est: 480.81M (+37.8%)
|
503.56M
est: 550.75M (-8.6%)
|
354.39M
est: 506.74M (-30.1%)
|
550.75M
550.75M – 550.75M
+8.7% YoY
|
606.76M
606.76M – 606.76M
+10.2% YoY
|
| EBIT |
68.54M
est: 101.78M (-32.7%)
|
100.89M
est: 92.28M (+9.3%)
|
112.07M
est: 118.29M (-5.3%)
|
139.41M
est: 101.78M (+37.0%)
|
208.67M
est: 92.28M (+126.1%)
|
119.72M
est: 118.29M (+1.2%)
|
146.56M
est.
|
328.63M
est: 337.90M (-2.7%)
|
392.63M
est: 391.05M (+0.4%)
|
588.35M
est: 391.05M (+50.5%)
|
409.60M
est: 451.74M (-9.3%)
|
243.99M
est: 415.65M (-41.3%)
|
451.74M
451.74M – 451.74M
+8.7% YoY
|
497.68M
497.68M – 497.68M
+10.2% YoY
|
| Net Income |
56.99M
est: 81.88M (-30.4%)
|
80.04M
est: 126.55M (-36.8%)
|
92.82M
est: 203.47M (-54.4%)
|
89.55M
est: 81.88M (+9.4%)
|
122.80M
est: 126.55M (-3.0%)
|
44.57M
est: 203.47M (-78.1%)
|
275.42M
est.
|
207.05M
est: 310.83M (-33.4%)
|
291.46M
est: 670.22M (-56.5%)
|
493.03M
est: 670.22M (-26.4%)
|
349.68M
est: 467.90M (-25.3%)
|
190.09M
est: 341.18M (-44.3%)
|
399.67M
399.67M – 399.67M
+17.1% YoY
|
497.15M
497.15M – 497.15M
+24.4% YoY
|
| SGA |
52.35M
est: 72.90M (-28.2%)
|
75.84M
est: 66.10M (+14.7%)
|
76.67M
est: 84.73M (-9.5%)
|
108.64M
est: 72.90M (+49.0%)
|
155.92M
est: 66.10M (+135.9%)
|
194.16M
est: 84.73M (+129.1%)
|
104.98M
est.
|
253.44M
est: 242.04M (+4.7%)
|
188.03M
est: 280.12M (-32.9%)
|
235.76M
est: 280.12M (-15.8%)
|
206.41M
est: 217.62M (-5.2%)
|
55.39M
est: 200.23M (-72.3%)
|
217.62M
217.62M – 217.62M
+8.7% YoY
|
239.75M
239.75M – 239.75M
+10.2% YoY
|
| EPS |
0.22
est: 0.17 (+30.5%)
|
0.24
est: 0.26 (-7.9%)
|
0.28
est: 0.42 (-33.2%)
|
0.27
est: 0.17 (+60.1%)
|
0.30
est: 0.26 (+15.1%)
|
0.09
est: 0.42 (-77.7%)
|
0.57
est.
|
0.43
est: 0.64 (-32.8%)
|
0.59
est: 1.38 (-57.2%)
|
1.05
est: 1.38 (-23.9%)
|
0.73
est: 0.96 (-24.0%)
|
0.39
est: 0.70 (-44.3%)
|
0.82
0.82 – 0.82
+17.1% YoY
|
1.02
1.02 – 1.02
+24.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-28 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-27 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-26 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-25 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-22 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-21 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-20 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-19 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-18 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-15 | B | 3/5 | 2/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-14 | B | 3/5 | 2/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-13 | B | 3/5 | 2/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-12 | B | 3/5 | 2/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-11 | B | 3/5 | 2/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | B | 3/5 | 2/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | B | 3/5 | 2/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | B | 3/5 | 2/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | B- | 3/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | B- | 2/5 | 2/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | B- | 2/5 | 2/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | B- | 2/5 | 2/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 194.7K | 0.39% |
| 2 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 10.2K | 0.44% |
| 3 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 102.9K | 0.29% |
| 4 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 70.8K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ai Min Liu | Chief Financial Officer & Financial Director | — | male |
| Dedong Zhang | Deputy General Manager | — | male |
| Haizhan Mao | Deputy General Manager | — | male |
| Jiangtao Yu | Senior Vice President & Director | — | male |
| Junzheng Zhang | Chairman of the Board & GM | — | male |
| Shegang Li | Deputy General Manager | — | male |
| Shigang Wang | Deputy General Manager | — | male |
| Xiaoliang Xing | Deputy GM & Board Secretary | — | male |
| Xiaowen Zou | Deputy General Manager | — | male |
| Yunxia Qu | Senior Vice President & Director | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300109.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
